About Us Contact Us Privacy Policy
© GOOD Worldwide Inc. All Rights Reserved.

FDA approves medicine that helps treat frostbite and save people from undergoing amputations

FDA approves Aurlumyn injection for frostbite treatment and could prove to be life-saving for many going forward.

FDA approves medicine that helps treat frostbite and save people from undergoing amputations
Cover Image Source - Getty Images I Jon Cherry

In cold conditions, people can face various health issues, including lung infections, making it crucial to keep warm. Illnesses like hypothermia and frostbite are significant risks in such temperatures. Frostbite, in particular, is a severe condition for which there is currently no medication available. At least not until now. The FDA has approved a special drug that could help cure frostbite and help prevent possible toe and finger amputation, reported Goodnews Network. 



The groundbreaking drug is called Aurlumyn (iloprost) injection. It can be used to treat the injury and also provide relief to patients who have been injured by frostbite. Frostbite is caused by frozen skin. In extreme cases, it leads to tissue damage and can force people to undergo amputations. Frostbites occur mainly in the feet and toes, so it's vital for people in cold conditions to keep those body parts well-covered and warm. Aurlumyn is said to contain a special ingredient named iloprost which works to heal affected blood vessels and can also prevent blood clots in the skin. 



Talking about the success of the new drug, Dr. Norman Stockbridge, director of the Division of Cardiology and Nephrology at the FDA's Center for Drug Evaluation and Research, has credited the FDA for approving the new frostbite drug. "This approval provides patients with the first-ever treatment option for severe frostbite," he told the FDA. "Having this new option provides physicians with a tool that will help prevent the life-changing amputation of one’s frostbitten fingers or toes."

However, the use of Iloprost isn't new in Canada, Nepal, and various European countries that depend on the drug. It remains to be seen how quickly pharmacists can get the drug onto the consumer market so it can start helping the general public.

More Stories on Good